Emyria Limited Provides Commentary On Half Year Results

Emyria accelerated its programs in psychedelic-assisted therapy, particularly the MDMA-Assisted Therapy for PTSD program after the TGA rescheduled MDMA and psilocybin in July 2023.

By Mr Michael Winlo

Emyria Limited (ASX: EMD), a leader in mental health and neurological treatments has provided a commentary for the half year ending December 31, 2023.

Key highlights

Board changes were implemented to support the company’s strategic direction in mental health innovation.

The company’s cash position stands at $1.97 million, bolstered by a significant R&D tax refund of $2.53 million received in January 2024.

Strategic Focus

With the TGA’s rescheduling of MDMA and psilocybin in July 2023, Emyria accelerated its programs in psychedelic-assisted therapy, particularly the MDMA-Assisted Therapy for PTSD program.

Initiatives were prioritized to align with the vision of becoming a global leader in psychedelic-assisted therapies, focusing on patient impact and value creation.

Key moves included acquiring the Pax Centre, securing regulatory approvals, and enhancing the Board with experts in scaling tech-supported clinical services.


  • Emyria is dedicated to demonstrating the commercial viability and clinical significance of its unique mental health care approach.
  • The focus is on evaluating the real-world efficacy of the MDMA-Assisted Therapy Model for PTSD treatment, aiming for payer support and global expansion.
  • Key business interests include expanding clinical services, scaling care delivery programs, capturing high-quality clinical data, advancing proprietary drug development programs, and optimizing intellectual property and financials.
  • Emyria remains committed to long-term growth, innovation, and improving patient care in the mental health sector.


The Group will concentrate on progressing its business interests, which include:

  • Expand clinical services by building on the momentum of integrating the Pax Centre, we aim to broaden our service offerings to address unmet medical needs, drive revenue growth and improve patient care.
  • Scale care delivery programs through organic growth and select partnerships while leveraging our clinical data to engage major Health Payers. Our goal is to enhance access to specialised mental health care and support for a broader patient base across Australia.
  • Capturing ethically sourced, high-quality clinical data with patients to transform the way novel therapies are understood and researched.
  • Advance proprietary drug development programs with world-leading institutions like the University of Western Australia (UWA) and the National institute of Health (NIH) utilising third-party funding support where possible.
  • Optimise Intellectual Property and Financials: With a favourable review of our MDMA analogue IP claims and growing revenues, we’re strategically advancing our high-potential projects while maintaining financial health and shareholder value.

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
[email protected]

Media Contact
Haley Chartres
+61 (0) 423 139 163
[email protected]

Articles of Interest